Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews

No studies found 2 · 33.3%GRADE not reported 0 · 0%Very low 1 · 16.7%Low 2 · 33.3%Moderate 1 · 16.7%High 0 · 0%

Efficacy: response (categorical) YMRS/SADS‐C decrease ≥ 50% by end of study · acute mania

The review found no eligible studies for this question.

1 finding from 1 review

Lithium for acute mania 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Efficacy: response (continuous) YMRS/BPRS change from baseline to end of study · acute mania

1 finding from 1 review

Lithium for acute mania 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 102 participants
Very low

Efficacy: response (continuous) CGI change from baseline to end of study · acute mania

1 finding from 1 review

Lithium for acute mania 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 76 participants
Moderate

Efficacy: remission (categorical) YMRS ≤ 12 and no increase in MADRS at end of study · acute mania

The review found no eligible studies for this question.

1 finding from 1 review

Lithium for acute mania 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Acceptability: total withdrawals · acute mania

Lithium showed no clear difference in acceptability: total withdrawals compared with carbamazepine (low certainty).

1 finding from 1 review

Lithium for acute mania 2019 · Cochrane Headline outcomes only
OR 0.2 [0.02, 1.94]
1 study · 34 participants
Low

Adverse effects: 1. Sedation · acute mania

Lithium showed no clear difference in adverse event: sedation compared with carbamazepine (low certainty).

1 finding from 1 review

Lithium for acute mania 2019 · Cochrane Headline outcomes only
OR 0.16 [0.01, 3.64]
1 study · 27 participants
Low